- Feb. 1 Pfizer/BioNTech asked the U.S. Food and Drug Administration to grant emergency use authorization (EUA) for their COVID shot to babies and children aged 6 months through 4 years.
- The EUA will be for a two-dose regimen, with the possibility of extending it to a third dose, as two injections have been shown to be ineffective in 2- to 4-year-olds.
- Children aged 6 months to 4 years will get a dose that is one-tenth the adult dose.
- Were Pfizer to wait until the triple-dose experiment is completed, the EUA request would not be possible until late March 2022, and federal officials are reportedly “anxious to begin a vaccination program for the youngest children because the studies showed there were no safety concerns with two doses.”
- Meanwhile, Pfizer’s own data raise massive safety concerns, as they received 42,086 injury reports, including 1,223 fatalities in the first 2.5 months of their COVID jab rollout for adults.